Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Short-term Investments: 2010-2021

Historic Short-term Investments for Neurocrine Biosciences (NBIX) over the last 11 years, with Sep 2021 value amounting to $454.8 million.

  • Neurocrine Biosciences' Short-term Investments fell 12.44% to $454.8 million in Q3 2021 from the same period last year, while for Sep 2021 it was $454.8 million, marking a year-over-year decrease of 12.44%. This contributed to the annual value of $613.9 million for FY2020, which is 9.98% up from last year.
  • According to the latest figures from Q3 2021, Neurocrine Biosciences' Short-term Investments is $454.8 million, which was down 12.01% from $516.9 million recorded in Q2 2021.
  • In the past 5 years, Neurocrine Biosciences' Short-term Investments registered a high of $613.9 million during Q4 2020, and its lowest value of $171.5 million during Q1 2017.
  • Its 3-year average for Short-term Investments is $521.5 million, with a median of $519.4 million in 2020.
  • As far as peak fluctuations go, Neurocrine Biosciences' Short-term Investments slumped by 35.58% in 2017, and later spiked by 94.93% in 2018.
  • Over the past 5 years, Neurocrine Biosciences' Short-term Investments (Quarterly) stood at $261.2 million in 2017, then surged by 94.93% to $509.2 million in 2018, then grew by 9.62% to $558.2 million in 2019, then increased by 9.98% to $613.9 million in 2020, then fell by 12.44% to $454.8 million in 2021.
  • Its Short-term Investments stands at $454.8 million for Q3 2021, versus $516.9 million for Q2 2021 and $521.1 million for Q1 2021.